NEW Zealand's medicines safety authority, Medsafe, stated a retrospective observational study suggests a potential increased risk of neurodevelopmental disorders in children whose fathers were treated with Epilim (sodium valproate), at the time of the child's conception compared to those treated with lamotrigine or levetiracetam.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 May 23
